OnlyBullishAlways Posted - 2 days ago

$HOWL one of my favorite stocks, but you have to know how to play it

DonCorleone77 Posted - 3 days ago

$HOWL Werewolf Therapeutics sees cash runway through at least 1Q26 As of March 31, 2024, cash and cash equivalents were $139.2 million, compared to $134.3 million as of December 31, 2023. The Company also had restricted cash and cash equivalents of $21.2 million as of both March 31, 2024 and December 31, 2023, of which $20.0 million became unrestricted upon the repayment of the Pacific Western Bank loan. The Company believes its existing cash and cash equivalents at March 31, 2024, together with cash impacts of the loan refinancing, will be sufficient to fund operational expenses and capital expenditure requirements through at least the first quarter of 2026.

DonCorleone77 Posted - 3 days ago

$HOWL Werewolf Therapeutics reports Q1 EPS (39c), consensus (35c) Reports Q1 revenue $742,000, consensus $1.82M. "Werewolf continues to focus on the execution of our lead clinical programs WTX-124 and WTX-330, with updates planned for later in the second quarter. At ASCO, we plan to share data from the dose-escalation portion of our Phase 1/1b trial evaluating WTX-124 as a single agent and in combination with pembrolizumab. In addition, we look forward to sharing interim, first-in-human monotherapy dose escalation data from the ongoing Phase 1/1b trial of WTX-330 in the second quarter." said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. "We continue to execute on our pipeline of INDUKINE molecules in oncology and immunology and are now projecting our financial runway to run through at least the first quarter of 2026."

Stock_Titan Posted - 3 days ago

$HOWL Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update https://www.stocktitan.net/news/HOWL/werewolf-therapeutics-reports-first-quarter-2024-financial-results-ypqzzvuryt79.html

DB_Daytrades Posted - 3 days ago

$HOWL uptrend still holding here looking for 7$ from here. Otherwise it’s bearish under 5.5-5.4

DB_Daytrades Posted - 04/30/24

$HOWL 7$+ will be the continuation but this trend line really needs to hold. Under 5.50 this trend breaks and I’m no longer bullish here.

DB_Daytrades Posted - 04/28/24

$HOWL daily view, 6.75+ this week can easily begin trending towards 8.20. 6$ and under is bearish.

Stock_Titan Posted - 04/24/24

$HOWL Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting https://www.stocktitan.net/news/HOWL/werewolf-therapeutics-announces-wtx-124-clinical-abstract-accepted-j7ohjtlr4wno.html

Scientwist Posted - 04/23/24

Werewolf Therapeutics is making strides with their PREDATOR™ platform, showing promising preclinical results for IBD treatment at IMMUNOLOGY™ 2024. Their innovative approach to immune-mediated diseases and cancer could be a game-changer. Definitely a company to watch! 🌟 #Biotech #Innovation $HOWL

DonCorleone77 Posted - 04/23/24

$HOWL Werewolf Therapeutics presents preclinical data on IL-10 INDUKINE molecules Werewolf Therapeutics announced a poster presenting preclinical data characterizing conditionally-activated IL-10 INDUKINE molecules for the treatment of colitis in animal models, a novel approach leveraging its PREDATOR protein engineering platform, at IMMUNOLOGY 2024, the annual meeting of the American Association of Immunologists taking place May 3-7 in Chicago, Illinois. According to the Centers for Disease Control and Prevention, IBD is a term that encompasses two conditions, Crohn's disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal tract. Prolonged inflammation results in damage to the GI tract. While the exact cause of IBD is unknown, autoimmune and immune-mediated factors have been shown to contribute to the severity of the disease. A groundbreaking study led by the Crohn's & Colitis Foundation finds that IBD is diagnosed in more than 0.7% of Americans, with 721 cases per 100,000 people, or nearly 1 in 100. Results highlighting Werewolf's findings are summarized in a poster titled, "Development of Conditionally Active IL-10 INDUKINE Molecules for the Treatment of Inflammatory Bowel Disease" Key takeaways are that Werewolf's IL-10 INDUKINE molecules: Contain human IL-10, a blocking domain, and a half-life extension domain tethered together by proprietary protease-sensitive linkers that are cleaved by UC and Crohn's human colon samples; Are peripherally inactive and conditionally active in the inflamed colon, where the IL-10 is released locally due to cleavage of the linkers in the dysregulated protease milieu; and Prevent weight loss and intestinal histological damage and inhibit inflammatory cytokine production within the colon in mouse models of colitis.

Stock_Titan Posted - 04/23/24

$HOWL Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting https://www.stocktitan.net/news/HOWL/werewolf-therapeutics-presents-first-preclinical-data-highlighting-gxzlwzftmffx.html

Biologix Posted - 04/22/24

Some current holdings: $CAPR (long) $SGMO (core to hold, swinging some) $HOWL $PFE (both long holds)

nevermind889 Posted - 04/15/24

$HOWL Glad this found bottom. Any news?

Will2ride1 Posted - 04/15/24

$HOWL dip and rip

Biologix Posted - 04/12/24

$HOWL i like it. Waiting to enter tho

Karp420 Posted - 04/08/24

$HOWL please

DonCorleone77 Posted - 1 month ago

$HOWL 3 of 3 - Werewolf Therapeutics to present data from studies of WTX-518, WTX-712 at AACR ....The WTX-712 data are summarized in a poster titled, "WTX-712, a conditionally active IL-21 INDUKINE molecule, induces a strong anti-tumor phenotype through a differentiated mechanism" (Abstract #4078). Key takeaways reveal that: WTX-712 demonstrates inducibility and antitumor activity with regressions in the MC38 mouse tumor model; IL-21 HLE has superior anti-tumor efficacy compared to IL-2 HLE therapy in mouse tumor models that are highly resistant to anti-PD-1/PD-L1 treatment, in part due to the activation of type-I IFN pathways; and IL-21 HLE promotes sustained expansion and activation of tumor infiltrating CD8 T cells with increased polyfunctionality and induces expression of cytotoxic effector molecules (Granzyme A, Granzyme B, and perforin). Werewolf plans to develop WTX-518 and WTX-712 as potential immunotherapies in refractory and/or immunologically unresponsive tumors.

DonCorleone77 Posted - 1 month ago

$HOWL 2 of 3 - Werewolf Therapeutics to present data from studies of WTX-518, WTX-712 at AACR ....These data collectively highlight the innovative strategies we are pursuing to further expand the repertoire of unique immune stimulating cytokine mechanisms in the fight against cancer." Results highlighting WTX-518 findings are summarized in a poster titled, "Discovery of WTX-518, an IL-18 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models" (Abstract #4074). Key takeaways reveal that WTX-518: is inducible, and its in vitro activity is not impeded by IL-18BP; selectively delivers active binding protein resistant IL-18 to the tumor microenvironment; and promotes increased influx and activation of NK cells and polyfunctional CD8 T cells in the TME, and demonstrates complete tumor regression in the MC38 mouse tumor model....

DonCorleone77 Posted - 1 month ago

$HOWL 1 of 3 - Werewolf Therapeutics to present data from studies of WTX-518, WTX-712 at AACR Werewolf Therapeutics is presenting preclinical data on development candidates WTX-518 and WTX-712 in posters at the American Association for Cancer Research Annual Meeting, taking place April 5-10 in San Diego, California."We are excited to share that both WTX-518 and WTX-712 demonstrate powerful immunotherapeutic effects in preclinical models," said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. "WTX-518 exhibits remarkable tumor-selective activation, resistance to IL-18BP and robust immune activation, overcoming key hurdles in the use of this promising cytokine in cancer therapy. WTX-712 acts through a unique mechanism that robustly activates tumor-specific T lymphocytes with an expanded therapeutic window through its selective release of wild-type IL-21 in the TME.....

Stock_Titan Posted - 1 month ago

$HOWL Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting https://www.stocktitan.net/news/HOWL/werewolf-therapeutics-presents-preclinical-results-demonstrating-rxu78mcah41u.html

Biotech_Beast Posted - 1 month ago

$HOWL Might have a competitive IL-12, even if GILD went for the $XLO drug instead. Also $MDNAF data on tap, with MDNA11, a competitor to HOWL's WTX-124. More WTX-124 and WTX-330 data are expected this quarter. https://seekingalpha.com/article/4682232-werewolf-therapeutics-in-the-hunt-for-success-in-the-cytokine-space

Stock_Titan Posted - 1 month ago

$HOWL Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting https://www.stocktitan.net/news/HOWL/werewolf-therapeutics-to-present-first-of-its-kind-data-byhdkp8zeijh.html

nevermind889 Posted - 1 month ago

$ARQT $FATE $HOWL Fantastic day!

nevermind889 Posted - 1 month ago

$ARQT $FATE $HOWL These guys always find a way to do well!

erevnon Posted - 1 month ago

JMP Securities initiates coverage on Werewolf Therapeutics $HOWL at Market Outperform and a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

AmbushPredator Posted - 1 month ago

$HOWL great buying opportunity today!

hick0ry2 Posted - 03/27/24

@hick0ry2 $howl back in

nevermind889 Posted - 03/27/24

$HOWL $ARQT $FATE Great recovery day!

StockMeister2 Posted - 03/18/24

$HOWL Werewolves of London again https://www.youtube.com/watch?v=qae25976UgA

Thelonius_Stonk Posted - 03/15/24

$HOWL interesting bio chart, backtesting breakout this week